Statements (89)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:approves |
gptkb:2017
gptkb:FDA |
| gptkbp:availability |
available in many countries
|
| gptkbp:clinical_trial |
gptkb:LIBERTY_ASTHMA_SYNERGY
Phase 3 chronic rhinosinusitis with nasal polyps moderate to severe atopic dermatitis eosinophilic esophagitis moderate to severe asthma LIBERTY AD CHRONOS LIBERTY ASTHMA QUEST LIBERTY NP SINUS LIBERTY ASTHMA VENTURE |
| gptkbp:clinical_use |
atopic dermatitis
asthma management chronic rhinosinusitis with nasal polyps |
| gptkbp:contraindication |
hypersensitivity to dupilumab
active or chronic infections |
| gptkbp:dosage_form |
solution for injection
|
| gptkbp:effective_date |
2017-03-28
|
| gptkbp:feedback |
generally positive
|
| gptkbp:financial_support |
available
|
| gptkbp:formulation |
auto-injector
pre-filled syringe |
| gptkbp:frequency |
once every two weeks
|
| gptkbp:healthcare |
gptkb:pharmaceuticals
|
| https://www.w3.org/2000/01/rdf-schema#label |
Dupixent
|
| gptkbp:indication |
moderate to severe asthma
|
| gptkbp:ingredients |
gptkb:dupilumab
|
| gptkbp:invention |
2027-10-01
|
| gptkbp:is_effective_against |
improves lung function
reduces asthma attacks reduces reliance on oral corticosteroids |
| gptkbp:is_monitored_by |
eye examinations
eosinophil counts |
| gptkbp:label |
black box warning for hypersensitivity
|
| gptkbp:long_term_use |
studied in clinical trials
|
| gptkbp:manufacturer |
gptkb:Sanofi
gptkb:Regeneron_Pharmaceuticals |
| gptkbp:marketed_as |
gptkb:Dupilumab
gptkb:Australia gptkb:Canada gptkb:European_Union gptkb:United_States |
| gptkbp:mechanism_of_action |
IL-4 and IL-13 inhibitor
|
| gptkbp:patient_education |
important for adherence
|
| gptkbp:patient_population |
adults and children 6 years and older
not controlled by inhaled corticosteroids |
| gptkbp:pharmacokinetics |
half-life of approximately 26 days
reduces Ig E levels reduces eosinophil levels |
| gptkbp:prescribing_restrictions |
requires healthcare provider supervision
|
| gptkbp:price |
high
approximately $37,000 per year |
| gptkbp:provides_guidance_on |
used in combination with other therapies
recommended for severe cases included in asthma management guidelines |
| gptkbp:regulatory_compliance |
FDA approved
EMA approved TGA approved approved in multiple regions |
| gptkbp:requires |
available online
|
| gptkbp:research |
ongoing for other indications
|
| gptkbp:research_focus |
cost-effectiveness analysis
impact on quality of life long-term safety effectiveness in different populations |
| gptkbp:route_of_administration |
subcutaneous injection
|
| gptkbp:safety_features |
generally well tolerated
|
| gptkbp:side_effect |
headache
allergic reactions increased risk of infections injection site reactions conjunctivitis eye problems serious allergic reactions oropharyngeal pain |
| gptkbp:storage |
refrigerated
|
| gptkbp:target_audience |
adults and children 6 years and older
|
| gptkbp:type_of_care |
self-administered
|
| gptkbp:used_for |
gptkb:asthma
treatment of asthma treatment of chronic rhinosinusitis with nasal polyps treatment of eczema |
| gptkbp:bfsParent |
gptkb:Sanofi
gptkb:Regeneron_Pharmaceuticals gptkb:Regeneron |
| gptkbp:bfsLayer |
4
|